These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 11866398

  • 1. Divalproex sodium in the treatment of migraine and cluster headaches.
    Gallagher RM, Mueller LL, Freitag FG.
    J Am Osteopath Assoc; 2002 Feb; 102(2):92-4. PubMed ID: 11866398
    [Abstract] [Full Text] [Related]

  • 2. Treatment of primary headache disorders with intravenous valproate: initial outpatient experience.
    Stillman MJ, Zajac D, Rybicki LA.
    Headache; 2004 Jan; 44(1):65-9. PubMed ID: 14979885
    [Abstract] [Full Text] [Related]

  • 3. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
    Mathew NT, Landy S, Stark S, Tietjen GE, Derosier FJ, White J, Lener SE, Bukenya D.
    Headache; 2009 Jul; 49(7):971-82. PubMed ID: 19486178
    [Abstract] [Full Text] [Related]

  • 4. Divalproex in the treatment of migraine.
    Freitag FG.
    Psychopharmacol Bull; 2003 Jul; 37 Suppl 2():98-115. PubMed ID: 15021865
    [Abstract] [Full Text] [Related]

  • 5. Valproate semisodium ER for migraine and cluster headache prophylaxis.
    Lovell BV, Marmura MJ.
    Expert Opin Drug Metab Toxicol; 2010 Apr; 6(4):495-504. PubMed ID: 20298131
    [Abstract] [Full Text] [Related]

  • 6. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine.
    Blumenfeld AM, Schim JD, Chippendale TJ.
    Headache; 2008 Feb; 48(2):210-20. PubMed ID: 18047502
    [Abstract] [Full Text] [Related]

  • 7. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

  • 8. Effect of divalproex on metabolic parameters is dose related in migraine prophylaxis.
    Green MW, Giordano S, Jiang P, Jafari M, Smith TB.
    Headache; 2005 Sep; 45(8):1031-7. PubMed ID: 16109117
    [Abstract] [Full Text] [Related]

  • 9. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM, BOTOX North American Episodic Migraine Study Group.
    Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
    [Abstract] [Full Text] [Related]

  • 10. Topiramate vs divalproex sodium in the preventive treatment of migraine: a prospective "real-world" study.
    Krymchantowski AV, Jevoux CC.
    Headache; 2011 Apr; 51(4):554-8. PubMed ID: 21457240
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of intravenous sodium valproate in the treatment of acute migraine.
    Waberzinek G, Marková J, Mastík J.
    Neuro Endocrinol Lett; 2007 Feb; 28(1):59-64. PubMed ID: 17277725
    [Abstract] [Full Text] [Related]

  • 12. Antiepileptic drugs in the prophylaxis of migraine, chronic headache forms and cluster headache: a review of their efficacy and tolerability.
    D'Amico D.
    Neurol Sci; 2007 May; 28 Suppl 2():S188-97. PubMed ID: 17508169
    [Abstract] [Full Text] [Related]

  • 13. Divalproex sodium extended-release for the prophylaxis of migraine headache in adolescents: results of a stand-alone, long-term open-label safety study.
    Apostol G, Lewis DW, Laforet GA, Robieson WZ, Fugate JM, Abi-Saab WM, Saltarelli MD.
    Headache; 2009 Jan; 49(1):45-53. PubMed ID: 19040679
    [Abstract] [Full Text] [Related]

  • 14. Safety and tolerability of divalproex sodium extended-release in the prophylaxis of migraine headaches: results of an open-label extension trial in adolescents.
    Apostol G, Pakalnis A, Laforet GA, Robieson WZ, Olson E, Abi-Saab WM, Saltarelli M.
    Headache; 2009 Jan; 49(1):36-44. PubMed ID: 19040678
    [Abstract] [Full Text] [Related]

  • 15. [Prophylactic treatments of migraine].
    Massiou H.
    Rev Neurol (Paris); 2000 Jan; 156 Suppl 4():4S79-86. PubMed ID: 11139754
    [Abstract] [Full Text] [Related]

  • 16. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis.
    Freitag FG, Collins SD, Carlson HA, Goldstein J, Saper J, Silberstein S, Mathew N, Winner PK, Deaton R, Sommerville K, Depakote ER Migraine Study Group.
    Neurology; 2002 Jun 11; 58(11):1652-9. PubMed ID: 12058094
    [Abstract] [Full Text] [Related]

  • 17. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS).
    Freitag FG, Finlayson G, Rapoport AM, Elkind AH, Diamond ML, Unger JR, Fisher AC, Armstrong RB, Hulihan JF, Greenberg SJ, AIMS Investigators.
    Headache; 2007 Apr 11; 47(4):519-30. PubMed ID: 17445101
    [Abstract] [Full Text] [Related]

  • 18. Significance of migrainous features in cluster headache: divalproex responsiveness.
    Wheeler SD.
    Headache; 1998 Apr 11; 38(7):547-51. PubMed ID: 15613172
    [Abstract] [Full Text] [Related]

  • 19. The efficacy of divalproex sodium in the prophylactic treatment of children with migraine.
    Caruso JM, Brown WD, Exil G, Gascon GG.
    Headache; 2000 Sep 11; 40(8):672-6. PubMed ID: 10971664
    [Abstract] [Full Text] [Related]

  • 20. Sumatriptan and naproxen sodium for the acute treatment of migraine.
    Smith TR, Sunshine A, Stark SR, Littlefield DE, Spruill SE, Alexander WJ.
    Headache; 2005 Sep 11; 45(8):983-91. PubMed ID: 16109111
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.